Month: April 2017

At Last, the Potential for a ONE-STICK Hospitalization

At Last, the Potential for a ONE-STICK Hospitalization

Our hearts go out to all the children whose childhoods are interrupted by hospitalization. Thankfully, there is a new and simple way to lessen their suffering—a unique vascular access device that finally offers hospitalized children the true potential for a ONE-STICK hospitalization. That wonderful addition to our vascular access toolbox is the 3Fr Pediatric POWERWAND™.

Children’s wards and Children’s Hospitals all over the country are celebrating the advent of this new, all-purpose Pediatric POWERWAND for its extraordinary first-attempt success rate, superb blood-drawability, extended dwell times (up to 29 days) and minimal complications. As an accomplished pediatric vascular specialist in the Midwest recently said, “It’s so nice to have mothers actually squeezing our hands and thanking us.  One told me the POWERWAND prevented her child from getting between 40-50 needlesticks.”

If your facility is a participant in the Children’s Hospitals Solutions for Patient Safety, you’ll be especially happy to learn that the Pediatric POWERWAND addresses 4+1 of the SPS Focus Goals. Used in conjunction with the Pediatric ZPad™ securement device and catheter cushion (which comes in the POWERWAND Pediatric kit, along with several other special accessories), the Pediatric POWERWAND is designed to reduce: (1) CLABSI, (2) Venous Thromboembolism, (3) PIVIEs (infiltrations and extravasations), (4) pressure injuries–PLUS (5) medical adhesive-related skin injuries.

The world of Pediatric vascular access just changed dramatically for the better.  The Pediatric POWERWAND—giving hospitalized children their first true shot at a ONE-STICK hospitalization.

I am confident this new POWERWAND product will add greatly to the daily gratification of your important work.  

 

Steve Bierman, MD

New Study Proves POWERWAND Safe for Vancomycin Delivery

New Study Proves POWERWAND Safe for Vancomycin Delivery

Definitive proof has finally arrived.  PICCs are no longer required to deliver long-term or short-term vancomycin (4mg/ml). Over 1000 patients, representing over 8000 catheter-days, are reported in this month’s JAVA to have had no DVTs and no bloodstream infections and minimal phlebitis (0.6%) during intravenous vancomycin administration through the POWERWAND midline. (Full article)

What does this groundbreaking study mean for you and your institution?

In most hospitals, vancomycin administration is an indication for about 20% of PICCs.  This new POWERWAND study demonstrates that these patients no longer need PICCs, which means you can reduce your central line days by roughly 20%. Instead of a PICC, a 4Fr or 5Fr POWERWAND placed in the deep vessels of the upper arm will get the job done safer and more cost-efficiently. In fact, placing a POWERWAND is usually at least $90.00 less expensive than placing a PICC.

Remember, only the POWERWAND midline has over 20,000 catheter days of published data attesting to zero bloodstream infections and the lowest complication rates of any vascular access device ever studied. (refs) Couple this with the news of safe vancomycin administration (over 5 years, in over 1000 patients) and you really have compelling reasons to support your POWERWAND use.

It’s a pleasure to share this information with you, because it means that everyone—patients and providers—gets to share the benefits POWERWAND use.  Thank you for your continued, evidence-based support.

Steve Bierman, MD

Chief Medical Officer